I believe we are topping out at around the $ 15.50/shr mark without news. The stock has been raising to the upper end of this channel and it is currently over-bought:

http://www.zshare.net/image/66158632d3f5...

Having said that, BVF could be targeted in the $ 25.00/shr range for late 2010 as many of their drugs will be approved or up for approval in one year's time. The chart has contained the stock since it hit it's lows last year. I'm writing call options against my position to achieve a higher price then I think it will go to over the next few months. If I get called away, I'll wait for a modest pull-back and write put options against it until I regain all of my shares at a lower price.

This is a great investment with WXL showing strength, investors are starting to forget about Melnyk and jumping in.